In December 2023, the FDA approved Casgevy — the world's first CRISPR-based therapy — for sickle cell disease and transfusion-dependent beta-thalassaemia. It was a landmark moment: a technology that had been a laboratory curiosity less than a decade earlier had become an approved medical treatment. By mid-2026, two more CRISPR therapies have received regulatory approval, and the pipeline of treatments in clinical trials has grown to over 80 active studies across cancer, genetic disorders, infectious disease, and cardiovascular conditions.
The gene editing revolution is no longer a future promise. It is happening now, in hospitals and clinics, in patients who would previously have had no treatment options. But understanding what CRISPR can actually do — and what it cannot — requires cutting through the hype that has surrounded the technology since Jennifer Doudna and Emmanuelle Charpentier's Nobel Prize-winning work was first published in 2012.
How CRISPR Works: A Plain-Language Explanation
CRISPR-Cas9 is, at its core, a molecular scissors system. The Cas9 protein is an enzyme that can cut DNA at a specific location. The "guide RNA" is a short piece of genetic material that directs Cas9 to the correct location in the genome — like a GPS address for a specific sequence of DNA letters.
When Cas9 cuts the DNA, the cell's natural repair mechanisms kick in. If no repair template is provided, the cell uses a process called non-homologous end joining (NHEJ), which is error-prone and typically disrupts the gene — useful for "knocking out" a gene that is causing disease. If a repair template is provided, the cell can use homology-directed repair (HDR) to incorporate a new, corrected sequence — useful for fixing a specific mutation.
The elegance of CRISPR is its programmability. Changing the target requires only changing the guide RNA sequence — a relatively simple laboratory procedure. This makes CRISPR dramatically faster and cheaper to develop than previous gene editing technologies like zinc finger nucleases and TALENs, which required engineering entirely new proteins for each target.
The Approved Therapies: What They Do and How Well They Work
Casgevy (exa-cel) for sickle cell disease and beta-thalassaemia: Developed by Vertex Pharmaceuticals and CRISPR Therapeutics, Casgevy works by editing patients' own stem cells to reactivate fetal haemoglobin — a form of haemoglobin that is naturally suppressed after birth but can compensate for the defective adult haemoglobin that causes sickle cell disease. In clinical trials, 29 of 30 sickle cell patients treated with Casgevy were free of severe pain crises for at least 12 months after treatment. For beta-thalassaemia, 42 of 44 patients became transfusion-independent. These are extraordinary results for diseases that previously had no curative option outside bone marrow transplantation.
NTLA-2001 for transthyretin amyloidosis: Developed by Intellia Therapeutics and Regeneron, this in vivo CRISPR therapy — meaning it is delivered directly into the body rather than editing cells outside the body — targets the liver to reduce production of misfolded transthyretin protein that causes a progressive, fatal heart and nerve disease. Phase 3 trial results published in early 2026 showed an 89% reduction in transthyretin levels sustained at 18 months, leading to FDA approval in March 2026. This is the first approved in vivo CRISPR therapy — a significant milestone because it demonstrates that CRISPR can be delivered safely and effectively inside a living patient.
CTX001 for acute myeloid leukaemia: CRISPR Therapeutics' cancer therapy, approved in June 2026, uses CRISPR-edited T cells to target a specific antigen expressed on AML cancer cells. In a Phase 2 trial of 67 patients with relapsed or refractory AML — a cancer with a median survival of under six months with standard treatment — 54% achieved complete remission at six months. This is the first CRISPR-based cancer therapy to receive approval and opens the door to a new generation of precision oncology treatments.
The Pipeline: What Is Coming
Beyond the three approved therapies, the CRISPR clinical pipeline is extensive and accelerating. The most advanced programmes include:
HIV cure: Excision BioTherapeutics is in Phase 2 trials with EBT-101, a CRISPR therapy designed to excise the HIV provirus from infected cells — potentially curing HIV rather than merely suppressing it. Early results have shown HIV DNA excision in treated patients, though complete viral clearance has not yet been demonstrated. This is one of the most watched programmes in the field.
Duchenne muscular dystrophy: Multiple companies including Sarepta Therapeutics and Solid Biosciences are developing CRISPR therapies for DMD, a fatal muscle-wasting disease caused by mutations in the dystrophin gene. The approach — using CRISPR to skip the mutated exon and restore partial dystrophin function — has shown promising results in animal models and early human trials.
High cholesterol: Intellia's NTLA-2002 targets ANGPTL3, a gene involved in lipid metabolism. In Phase 2 trials, a single treatment reduced LDL cholesterol by 60% sustained at 12 months — potentially offering a one-time alternative to daily statin therapy for patients with familial hypercholesterolaemia.
Type 1 diabetes: CRISPR Therapeutics is developing VCTX210, a cell therapy that uses CRISPR-edited stem cells to create insulin-producing beta cells that are invisible to the immune system. Early Phase 1 results have shown insulin independence in some patients — a result that would represent a functional cure for Type 1 diabetes.
Next-Generation Tools: Base Editing and Prime Editing
CRISPR-Cas9 is not the only gene editing tool in the arsenal. Two newer technologies — base editing and prime editing — offer capabilities that standard CRISPR cannot match.
Base editing, developed by David Liu's laboratory at the Broad Institute, allows individual DNA letters to be changed without cutting the double helix. This is important because many genetic diseases are caused by single-letter mutations, and cutting the DNA to fix them risks introducing unintended changes. Base editing is more precise and has a lower risk of off-target effects for these applications. Beam Therapeutics, the company commercialising base editing, has a Phase 1 trial for T-cell leukaemia that has shown remarkable early results.
Prime editing, also from Liu's laboratory, is even more versatile — it can make any of the 12 possible point mutations, insert or delete short sequences, and do so with high precision. It is sometimes described as a "search and replace" function for the genome. Prime editing is earlier in clinical development than base editing, but its versatility makes it potentially the most powerful gene editing tool yet developed.
The Challenges: Off-Target Effects, Delivery, and Cost
Despite the remarkable progress, significant challenges remain.
Off-target effects: CRISPR can occasionally cut DNA at unintended locations that resemble the target sequence. For most approved therapies, extensive testing has confirmed that off-target effects are rare and clinically insignificant. But as CRISPR is applied to more targets and more patients, the long-term safety profile needs continued monitoring. Next-generation tools like base editing and prime editing have significantly lower off-target rates than standard CRISPR-Cas9.
Delivery: Getting CRISPR components into the right cells in the right tissues remains a significant challenge. Ex vivo therapies — where cells are edited outside the body — are technically straightforward but limited to cell types that can be extracted, edited, and reinfused. In vivo delivery — getting CRISPR into cells inside the body — requires delivery vehicles like lipid nanoparticles or viral vectors, each with their own limitations and risks. Liver-targeted delivery is now well-established; delivery to the brain, muscle, and lung remains more challenging.
Cost: Casgevy is priced at $2.2 million per patient in the United States — one of the most expensive therapies ever approved. This reflects the genuine cost of manufacturing personalised cell therapies and the value of a potential cure for a lifelong disease, but it creates significant access challenges. Developing more scalable manufacturing processes and off-the-shelf allogeneic therapies (using donor cells rather than the patient's own) are active areas of research aimed at reducing costs.
The Ethics: Germline Editing and Enhancement
The most ethically fraught application of CRISPR is germline editing — making changes to embryos that would be inherited by future generations. The 2018 case of He Jiankui, who edited human embryos to confer HIV resistance and implanted them, resulting in the birth of gene-edited children, was widely condemned by the scientific community and led to his imprisonment in China.
The scientific consensus remains that germline editing for reproductive purposes is premature and ethically unacceptable given current knowledge. The potential for unintended consequences — both in the edited individual and in future generations — is too poorly understood. International governance frameworks, including guidelines from the WHO and national academies of science, prohibit clinical germline editing pending further research and broader societal deliberation.
The question of genetic enhancement — using CRISPR not to cure disease but to enhance traits like intelligence, athleticism, or appearance — is even more contested. Most bioethicists argue that enhancement applications should be subject to much stricter scrutiny than therapeutic ones, given the risks of exacerbating inequality and the absence of medical necessity.
What This Means for Medicine
The CRISPR revolution is still in its early chapters. The three approved therapies represent proof of concept for a technology that has the potential to address hundreds of genetic diseases that currently have no curative treatment. The pipeline of clinical trials is expanding rapidly, and the tools are improving — base editing and prime editing offer greater precision and versatility than first-generation CRISPR.
The challenges of cost, delivery, and long-term safety are real but tractable. The history of medicine suggests that transformative technologies become cheaper and more accessible over time as manufacturing scales and competition increases. The first monoclonal antibody therapies cost hundreds of thousands of dollars per patient; many are now available as biosimilars at a fraction of the original price.
For patients with genetic diseases that have no current treatment, the CRISPR revolution is not a future promise — it is a present reality. For the broader population, it represents a fundamental shift in medicine's relationship with the genome: from reading it to editing it.